US explores China biotech restrictions, exempts licensing deals

A new proposal from the U.S. government seeking to address investment in Chinese biotech as a matter of national security drew cautious statements from across the industry, with leaders vowing to ensure innovation isn’t stifled.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top